TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15240584
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment (0.074 mg/kg, sc three times per week)
Study: 12191749
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy (60% inhaled oxygen)
Study: 9707845
Drug: KOH preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: KOH preparation
Study: 9707845
Drug: KOH preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: KOH preparation and CFW
Study: 407963
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition with a high calorie and nitrogen content (group A)
Study: 407963
Drug: Intravenous dextrose/saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextrose/saline solution (group B)
Study: 31271193
Drug: Phenylalanine intake
Normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylalanine intake ranging from 7.20 to 40.0 mg .kg‐1 .d‐1
Study: 31271193
Drug: Adaptation to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptation to a milkshake diet providing protein at 1.0 g.kg‐1 .d‐1 and energy at 1.7 × REE for two days prior to study
Study: 31271193
Drug: Direct amino
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct amino acid oxidation method measuring oxidation of l‐[1‐13C]phenylalanine to 13CO2
Study: 25993119
Drug: Anifrolumab (anti-IFNAR1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anifrolumab (anti-IFNAR1 receptor antibody)
Study: 24925440
Drug: Voriconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (400 mg every 12 h on day 1, then 300 mg every 12 h for 27.5 days)
Study: 19317630
Drug: Other antidepressants
Normalized name: Other antidepressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antidepressants (citalopram, duloxetine, fluoxetine, paroxetine, sertraline, venlafaxine)
Study: 12365828
Drug: Intra-arterial thrombolysis
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial thrombolysis with other agents
Study: 8545790
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Split course radiotherapy (1.8 to 2 Gy single dose) over 10 weeks with chemotherapy (5‐FU, methotrexate, cyclophosphamide)
Study: 8545790
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Conventional radiotherapy (1.8 to 2 Gy single dose) over 6 weeks with chemotherapy (5‐FU, mitomycin C)
Study: 30878323
Drug: Probiotics (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (daily capsules containing Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12)
Study: 27634419
Drug: NGF injection
Normalized name: Panthenol 1 g in 100 mL TOPICAL SOLUTION [NGF 574H HAIR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGF injection in infrapatellar fat pad (IFP) followed by acid infusion (5 mL of phosphate-buffered acidic saline at 20 mL/h)
Study: 27634419
Drug: NGF injection
Normalized name: Panthenol 1 g in 100 mL TOPICAL SOLUTION [NGF 574H HAIR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGF injection in tibialis anterior (TA) muscle followed by acid infusion (10 mL at 30 mL/h)
Study: 27634419
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection in infrapatellar fat pad (IFP) followed by acid infusion (5 mL of phosphate-buffered acidic saline at 20 mL/h)
Study: 27634419
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection in tibialis anterior (TA) muscle followed by acid infusion (10 mL at 30 mL/h)
Study: 25843816
Drug: Submucosal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Submucosal dexamethasone 8 mg
Study: 24716610
Drug: Intravenous KGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous KGF (60 μg/kg) for 3 days
Study: 24716610
Drug: Inhibition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibition of GM-CSF receptor activation
Study: 15450725
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment time of radiotherapy reduced to 5.5 weeks, 6.5 weeks, and 9.5 weeks with a total dose of 66-68 Gy, 2 Gy/fx.
Study: 9746769
Drug: D-FISH technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-FISH technique for monitoring therapy in CML
Study: 7911136
Drug: 250-micrograms bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-micrograms bolus injection of somatostatin + 250 micrograms/h slow infusion
Study: 7911136
Drug: 500-micrograms bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-micrograms bolus injection of somatostatin + 250 micrograms/h slow infusion
Study: 3295548
Drug: Control (therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (therapy without photocoagulation)
Study: 29405252
Drug: Standard follow-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard follow-up (measurement of calcium and parathyroid hormone on postoperative day 1 and systematic supplementation with calcium and vitamin D; control group)
Study: 12085976
Drug: Aprotinin (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (280 mg in pump prime)
Study: 8465822
Drug: Glucose-polymer solution
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-polymer solution
Study: 3079994
Drug: Branched chain‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched chain‐enriched amino acid solutions (valine-enriched)
Study: 3079994
Drug: Branched chain‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched chain‐enriched amino acid solutions (leucine-enriched)
Study: 30336598
Drug: Iron Treatment
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron Treatment Group (ITG) - 325mg/d of ferrous sulphate for 11 weeks
Study: 30336598
Drug: Iron Treatment
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron Treatment Group (ITG)
Study: 23528388
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (5 days/week, 2 sessions/day for 21 days, 15 min/session)
Study: 23528388
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation program without mirror therapy
Study: 21627403
Drug: High-dose parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose parenteral polyoestradiol phosphate (PEP) 240 mg i.m. twice a month for 2 months and thereafter monthly
Study: 21627403
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen deprivation (CAD) with flutamide (Eulexin®) 250 mg per os three times daily and triptorelin (Decapeptyl®) 3.75 mg i.m. per month or bilateral orchidectomy
Study: 18757238
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day
Study: 18757238
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel once a day
Study: 18757238
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg telmisartan once per day
Study: 12908135
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation strategies
Study: 12908135
Drug: Platinum and
Normalized name: Platinum and/or platinum compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum and 5-fluorouracil drug combinations
Study: 12908135
Drug: New biologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New biologic agents in combined modality treatment schemes
Study: 11127445
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of enalapril (mean dose achieved 17.9 mg/day)
Study: 11127445
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of enalapril (mean dose achieved 42 mg/day)
Study: 2154428
Drug: Azithromycin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (three regimens including a single oral dose)
Study: 2154428
Drug: Doxycycline (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (standard treatment)
Study: 26218852
Drug: Cortisol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (20 mg, single oral dose)
Study: 23727103
Drug: Midazolam (Mi)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (Mi) + Morphine (Mo)
Study: 23727103
Drug: Morphine (Mo)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (Mo) alone
Study: 20049561
Drug: Palonosetron (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.25 mg i.v.)
Study: 20049561
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg i.v.)
Study: 19288149
Drug: Sea buckthorn
Normalized name: sea buckthorn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sea buckthorn berries (SBB), 28 g daily for 3 months
Study: 15599835
Drug: Milrinone infusion
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone infusion for 48 to 72 hours
Study: 15599835
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 48 to 72 hours
Study: 9300324
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amlodipine and hydrochlorothiazide
Study: 7944426
Drug: Postoperative intrahepatic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intrahepatic arterial infusion with Farmorubicin and 5‐FU (i.a group)
Study: 2976670
Drug: Enoximone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (3 mg/kg oral and 1 mg/kg i.v.)
Study: 30100052
Drug: Low-moderate epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-moderate epinephrine doses
Study: 15062137
Drug: Brachytherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachytherapy with supplemental external beam radiation therapy (XRT)
Study: 15062137
Drug: Brachytherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brachytherapy without supplemental external beam radiation therapy (XRT)
Study: 1333960
Drug: Urodilatin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urodilatin (4 micrograms kg‐1 bw, two high dose intravenous bolus injections at a 30 min interval, n = 6)
Study: 1333960
Drug: ANF(99‐126) (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANF(99‐126) (4 micrograms kg‐1 bw, same dosing as Urodilatin, n = 6)
Study: 30915366
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection combined with miniscalpel-needle (MSN) release
Study: 25040756
Drug: Tramadol 2
Normalized name: traMADol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 2 mg·kg(‐1) 6-hourly for up to 5 days
Study: 25040756
Drug: Placebo 6-hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 6-hourly for up to 5 days
Study: 20025149
Drug: NG‐nitro‐L‐arginine‐methyl‐ester (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐nitro‐L‐arginine‐methyl‐ester (1 mg x kg(‐1))
Study: 15889234
Drug: Metformin (850-2,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850-2,550 mg/day)
Study: 12485118
Drug: lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 60 mg once a day (qd)
Study: 12485118
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg twice a day (bid)
Study: 9787889
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg daily
Study: 7649971
Drug: Higher-dose range
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose range nefazodone (100-600 mg/day)
Study: 7649971
Drug: Placebo (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2-6 capsules per day)
Study: 7649971
Drug: Lower-dose range
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose range nefazodone (50-300 mg/day)
Study: 1221110
Drug: Ethanol (0.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.67 g/kg body weight) ingested at 0700
Study: 1221110
Drug: Ethanol (0.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.67 g/kg body weight) ingested at 1100
Study: 1221110
Drug: Ethanol (0.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.67 g/kg body weight) ingested at 1900
Study: 1221110
Drug: Ethanol (0.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.67 g/kg body weight) ingested at 2300
Study: 17984346
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rifampin and azithromycin
Study: 7525633
Drug: 0.02 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg/kg BW.day recombinant human GH (rhGH)
Study: 3037812
Drug: RIT 4256
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT 4256 vaccine in adults
Study: 3037812
Drug: RIT 4256
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT 4256 vaccine in 6-month-old children
Study: 3037812
Drug: RIT 4256
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT 4256 vaccine in newborn infants
Study: 3037812
Drug: RIT 4237
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT 4237 vaccine in newborn infants
Study: 3037812
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of RIT 4256 and RIT 4237 vaccines
Study: 30260251
Drug: 3 mL/kg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL/kg of 3% HS (group L)
Study: 30260251
Drug: 5 mL/kg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/kg of 3% HS (group H)
Study: 27165280
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg and 5 mg
Study: 20724648
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg alogliptin plus 30 mg pioglitazone (A25+P30)
Study: 20724648
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg alogliptin (A25)
Study: 20724648
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone (P30)
Study: 18772723
Drug: Viscous marketed
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Viscous marketed artificial tear formulations (test formulation)
Study: 7674700
Drug: Ketoprofen solution
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen solution (25 mg)
Study: 7674700
Drug: Ketoprofen tablet
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen tablet (2.5 mg)
Study: 7012668
Drug: Allopurinol therapy
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol therapy
Study: 31104280
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg netupitant/0.5 mg palonosetron
Study: 24570327
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) intravenous infusion of 20 ng/kg/min for 6 hours before and after contrast media administration
Study: 24570327
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution for routine hydration (control group)
Study: 22024226
Drug: PEG-IFN a-2b/RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-IFN a-2b/RBV therapy (Secondary IFN group)
Study: 17223306
Drug: Continuous iliofascial
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous iliofascial nerve sheath block (KT group) with 30 ml of ropivacaïne 4.75 mg/ml and 14 mg/h of ropivacaïne 2 mg/ml for 48 hours
Study: 16753936
Drug: Aortic valve-sparing
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic valve-sparing operations (David I reimplantation technique, Gel-weave Valsalva graft)
Study: 12648174
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg misoprostol initially then a further identical dose 6 h later
Study: 12648174
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dinoprostone initially followed by 1 mg 6 h later
Study: 12648174
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dinoprostone
Study: 8842782
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg initial dose followed by 20 mg tid for 5 days)
Study: 1495860
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 1,000 micrograms daily
Study: 6406654
Drug: L-carnitine IV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine IV, 10 mg/kg . day
Study: 26902504
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone furoate (FF) and vilanterol (VI) combination therapy
Study: 26902504
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone furoate (FF)
Study: 26902504
Drug: Inhaled vilanterol
Normalized name: fluticasone / vilanterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled vilanterol (VI)
Study: 15692889
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone for one month (first week) and topical fluormetalone for the next three weeks
Study: 15692889
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone for one week
Study: 7028533
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (25 mg for ages 2-5 years; 50 mg for ages 6-10 years)
Study: 25614155
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg/day plus Serenoa repens 320 mg/day
Study: 25614155
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg/day only
Study: 23617610
Drug: Nucleus(®) cochlear
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleus(®) cochlear implant fitting suite
Study: 21508862
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (2 weeks and 4 weeks duration)
Study: 19825324
Drug: Paliperidone immediate-release
Normalized name: paliperidone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone immediate-release (IR) 1 mg dose
Study: 16869814
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of cefotaxime (2 g over 24 h plus a loading dose of 1 g)
Study: 16869814
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of cefotaxime (1 g three times daily)
Study: 15200652
Drug: Ropivacaine (0.4%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (0.4%, 2 mg x kg(‐1))
Study: 15200652
Drug: Ropivacaine (0.2%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (0.2%, 1 mg x kg(‐1)) plus ketamine (0.25 mg x kg(‐1))
Study: 15200652
Drug: Ropivacaine (0.2%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (0.2%, 1 mg x kg(‐1)) plus tramadol (1 mg x kg(‐1))
Study: 9549662
Drug: Metrifonate (LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (LD = 1.5 mg/kg, MD = 0.25 mg/kg)
Study: 9549662
Drug: Metrifonate (LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (LD = 2.5 mg/kg, MD = 0.40 mg/kg)
Study: 9549662
Drug: Metrifonate (LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (LD = 4.0 mg/kg, MD = 0.65 mg/kg)
Study: 9549662
Drug: Metrifonate (LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (LD = 4.0 mg/kg, MD = 1.0 mg/kg)
Study: 9549662
Drug: Metrifonate (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (highest doses)
Study: 2731781
Drug: Ticlopidine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 500 mg/day
Study: 27939089
Drug: Intervention A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention A: 12-session treatment program including discussion of low back pain experience, graded sensory training, graded motor imagery training, and functional movement training.
Study: 27939089
Drug: Intervention B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention B: 12-session treatment program including discussion of low back pain experience, transcranial direct current stimulation, cranial electrical stimulation, low-intensity laser therapy, and pulsed electromagnetic energy.
Study: 21372302
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day simvastatin
Study: 18669979
Drug: ezetimibe/simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/20 mg/day
Study: 22088245
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg/d) plus Irbesartan (150 mg/d)